33.04
前日終値:
$33.16
開ける:
$33.05
24時間の取引高:
1.39M
Relative Volume:
0.69
時価総額:
$4.13B
収益:
$18.47M
当期純損益:
$-589.53M
株価収益率:
-6.2814
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
+1.23%
1か月 パフォーマンス:
+6.51%
6か月 パフォーマンス:
-29.76%
1年 パフォーマンス:
-39.02%
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CYTK
Cytokinetics Inc
|
33.04 | 4.13B | 18.47M | -589.53M | -399.80M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-24 | 開始されました | Barclays | Overweight |
2025-02-07 | 開始されました | Citigroup | Buy |
2025-01-22 | 開始されました | Stifel | Buy |
2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
2024-01-24 | ダウングレード | UBS | Buy → Neutral |
2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-11-09 | 開始されました | Goldman | Buy |
2023-11-07 | 開始されました | B. Riley Securities | Buy |
2023-08-15 | 開始されました | SVB Securities | Outperform |
2023-02-17 | 開始されました | BofA Securities | Neutral |
2022-12-23 | 繰り返されました | Needham | Buy |
2022-12-20 | 開始されました | Truist | Buy |
2022-10-11 | 開始されました | UBS | Buy |
2022-01-28 | 開始されました | Goldman | Buy |
2021-12-22 | 開始されました | Oppenheimer | Outperform |
2021-12-10 | 開始されました | JP Morgan | Overweight |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-03-12 | 開始されました | Wolfe Research | Outperform |
2021-02-18 | 開始されました | Barclays | Overweight |
2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-29 | 開始されました | Goldman | Neutral |
2020-07-10 | 開始されました | Raymond James | Strong Buy |
2020-05-05 | 開始されました | Mizuho | Buy |
2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
2017-07-31 | 開始されました | Morgan Stanley | Overweight |
2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
2016-07-28 | 繰り返されました | Needham | Buy |
2015-11-10 | 繰り返されました | FBR Capital | Outperform |
2015-11-09 | 繰り返されました | ROTH Capital | Buy |
2015-07-24 | 繰り返されました | MLV & Co | Buy |
2014-12-31 | 繰り返されました | ROTH Capital | Buy |
2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire
Cytokinetics CEO Robert Blum sells $169,000 in stock By Investing.com - Investing.com Canada
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook - Investing.com
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times
JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | CYTK Stock News - GuruFocus
Cytokinetics (CYTK) Target Price Cut by JPMorgan Analyst | CYTK Stock News - GuruFocus
JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | C - GuruFocus
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - mx.advfn.com
Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion By Investing.com - Investing.com Nigeria
Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion - Investing.com India
Cetera Investment Advisers Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Mizuho - Defense World
Recognizing Hypertrophic Cardiomyopathy in Women: Addressing Misdiagnosis - HCPLive
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | C - GuruFocus
Cytokinetics (CYTK) Gets Price Target Reduction from Mizuho Anal - GuruFocus
Cytokinetics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | CYTK Stock News - GuruFocus
Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating - marketscreener.com
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Cytokinetics at RBC Conference: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation - ACCESS Newswire
BNP Paribas Financial Markets Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM T - GuruFocus
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus
Cytokinetics Presents Additional Data Related to Aficamten at th - GuruFocus
Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics (NASDAQ:CYTK) Upgraded at Cantor Fitzgerald - Defense World
Cytokinetics Grants $1.2M in Equity Awards: New Hires Signal Growth in Cardiovascular Drug Development - Stock Titan
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from Needham & Company LLC - Defense World
Insider Sell: Muna Bhanji Sells 1,454 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics to Host Symposium on Contemporary Landscapes in Mus - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | C - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | CYTK Stock News - GuruFocus
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Malik Fady Ibraham | EVP Research & Development |
Jun 17 '25 |
Sale |
32.91 |
2,000 |
65,820 |
140,610 |
Blum Robert I | President & CEO |
Jun 16 '25 |
Sale |
33.80 |
5,000 |
169,000 |
403,108 |
大文字化:
|
ボリューム (24 時間):